Bio-Works Technologies AB (FRA:1BD) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1BD Bio-Works Technologies AB FRA:1BD
49 GF Score
Price €0.29
GF Value €0.32
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Bio-Works Technologies AB Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Bio-Works Technologies AB is: High Risk: High uncertainty with risk-return tradeoff.

Bio-Works Technologies AB  (FRA:1BD) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Bio-Works Technologies AB Risk Assessment Related Terms

FRA:1BD vs ISRG, BDX, MDLN: Risk Assessment Comparison

For the Medical Instruments & Supplies subindustry, Bio-Works Technologies AB's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Works Technologies AB Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Works Technologies AB's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Bio-Works Technologies AB's Risk Assessment falls into.


FRA:1BD
49GF Score
Bio-Works Technologies AB FRA:1BD
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bio-Works Technologies AB (FRA:1BD) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Works Technologies AB stock appears to be undervalued. The current stock price of €0.29 is trading 10.6% below its estimated GF Value™ of €0.32. GuruFocus considers Bio-Works Technologies AB to be Modestly Undervalued.

Key valuation signals for FRA:1BD:

  • Risk Assessment:
  • GF Value™: €0.32 vs. price of €0.29 (10.6% below fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the FRA:1BD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Works Technologies AB Business Description

Other Exchanges BIOWKS:Sweden
Address Virdings alle 18, Uppsala, SWE, 75450
Bio-Works Technologies AB is a Sweden-based life science company which is engaged in designing, developing, manufacturing and supplying products for purification and separation of proteins and other molecules. The product line of the company includes activated resin, immobilized metal-ion affinity chromatography resin, ion exchange chromatography resin, size exclusion chromatography resin and others. The company has also developed affinity chromatography technique, BabyBio Columns, OptiBio glass columns for separating proteins, and protein purification. Bio-Works serves various end users such as academic research laboratories, biopharmaceutical companies, the food and beverage industry and others.
49GF Score

Get the complete analysis for FRA:1BD

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.29
Price
€0.32
GF Value